McKesson acquires Precision Medicine from Blackstone
- McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion
- Blackstone is the seller
- The Oncology and Multispecialty segment posted $14.2 billion in quarterly revenue
- That is a 33% year-over-year increase
TEXAS and MARYLAND, UNITED STATES — McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group from Blackstone for approximately $2.25 billion.
The purchase adds biomarker intelligence, laboratory services, a global contract research organization, market access consulting, and drug commercialization support to McKesson’s oncology and specialty care portfolio. Closing is subject to customary regulatory clearances.
Oncology capital strategy anchors $2.25 billion deal
According to a report from Lawrence Evans, McKesson said the acquisition of Precision Medicine Group aligns with its strategy of concentrating capital in oncology and specialty care.
The company’s Oncology and Multispecialty segment posted $14.2 billion in revenue in fiscal first-quarter 2026, a 33% year-over-year increase, and McKesson has committed to this segment as its primary growth axis.
The deal gives McKesson an owned global contract research organization (CRO), a biomarker intelligence platform, and laboratory analysis capabilities: knowledge process outsourcing (KPO) functions the company had previously accessed through external partnerships rather than owned assets.
Blackstone exit marks precision oncology payoff
Precision Medicine Group said its market access consulting and drug commercialization support services are built to serve pharmaceutical manufacturers across the full clinical-to-commercial lifecycle, extending McKesson’s role beyond drug distribution into research and launch strategy.
Blackstone’s exit at approximately $2.25 billion reflects the premium that large health services acquirers now place on scaled managed services platforms in oncology, where CRO capabilities and biomarker data assets command valuations above those of traditional distribution businesses.
McKesson said it does not anticipate any disruption to Precision Medicine Group’s existing client relationships through or following the close of the transaction.
The McKesson-Precision Medicine Group acquisition reflects accelerating consolidation in oncology services, where distributors and health systems are acquiring clinical research and market access capabilities once confined to standalone CRO firms.
For the healthcare outsourcing sector, the transaction signals that pharmaceutical manufacturers increasingly expect outsourced partners to manage the full pathway from laboratory biomarker analysis through drug launch rather than discrete functions delivered by separate vendors.
At $2.25 billion, the deal illustrates that precision medicine services platforms carrying robust data assets and commercialization expertise command significant strategic multiples.
As oncology drug pipelines grow in complexity, the ability to combine CRO operations with go-to-market strategy is becoming a structural differentiator for companies operating at the intersection of health services and outsourced pharmaceutical support.
Related news
- Knox Lane acquires Cross Country Healthcare · 21 Jul
- Health Catalyst completes Vitalware sale · 12 Aug
- CRC Advisors buys BBKS & Co · 8 Aug
Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication.
Stay ahead of the outsourcing industry. Join thousands of business leaders who rely on Outsource Accelerator for the news, trends, and expert insights that matter. Subscribe to our free newsletter and never miss an update.
